' 
![]()
SCIENTIFIC SCORE
Questionable
Based on 2 Researches
5
USERS' SCORE
Good
Based on 1 Review
8.6
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%*
Polyunsaturated Fat
1 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Docosahexaenoic Acid (DHA)
500 mg
†
Eicosapentaenoic Acid (EPA)
250 mg
†
Top Medical Research Studies
5
DHA effects on IBS unclear
Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel syndrome.
Combination treatment explored, limited findings
We aimed to understand the role of docosahexaenoic acid (DHA) in the context of irritable bowel syndrome (IBS) by investigating how it works alongside Bifidobacterium breve and essential fatty acids, namely α-linolenic acid and linoleic acid.
Our study involved maternally separated and non-separated rats, who received different dietary supplements for a period of seven weeks. We specifically looked for changes in colonic sensitivity and fatty acid profiles in various tissues, comparing supplemented and control groups.
The results showed that feeding B. breve to maternally separated rats notably increased levels of palmitoleic acid, arachidonic acid, and DHA in their liver, along with adjustments in other fatty acids within brain and body fat tissues. However, the same supplementation in non-separated rats elevated other fatty acids, with a significant boost in eicosapentaenoic acid and docosapentaenoic acid in their serum.
Overall, while we observed that DHA levels adjusted in response to the supplementations, the specific effects of DHA on IBS symptoms remain unclear, especially since it was administered in combination with other treatments. This indicates that more focused research on DHA alone is necessary to fully gauge its impact on IBS.
Our study involved maternally separated and non-separated rats, who received different dietary supplements for a period of seven weeks. We specifically looked for changes in colonic sensitivity and fatty acid profiles in various tissues, comparing supplemented and control groups.
The results showed that feeding B. breve to maternally separated rats notably increased levels of palmitoleic acid, arachidonic acid, and DHA in their liver, along with adjustments in other fatty acids within brain and body fat tissues. However, the same supplementation in non-separated rats elevated other fatty acids, with a significant boost in eicosapentaenoic acid and docosapentaenoic acid in their serum.
Overall, while we observed that DHA levels adjusted in response to the supplementations, the specific effects of DHA on IBS symptoms remain unclear, especially since it was administered in combination with other treatments. This indicates that more focused research on DHA alone is necessary to fully gauge its impact on IBS.
Read More
5
Fatty acids affect IBS metabolism
Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel syndrome.
Limited direct evidence of eicosapentaenoic acid
Our study focused on understanding how eicosapentaenoic acid, alongside other fatty acids, influences irritable bowel syndrome (IBS). We designed an experiment where we treated both maternally separated and non-separated rats with Bifidobacterium breve and explored its effect on colonic sensitivity and fatty acid metabolism over a period of seven weeks.
Throughout our research, we observed significant changes in fatty acid profiles, especially in liver and serum tissues, after administering Bifidobacterium breve. Notably, in the maternally separated rats, the treatment appeared to enhance levels of palmitoleic acid, arachidonic acid, and docosahexaenoic acid in various tissues, which are fatty acids that others believe could be influential in managing symptoms related to IBS.
However, while eicosapentaenoic acid was present in the research context, it was largely studied in combination with other treatments. This made it challenging to evaluate its isolated effect on IBS directly. Thus, while we noted some positive metabolic changes with our treatment approach, the specific impact of eicosapentaenoic acid on IBS symptoms wasn’t definitively established.
Overall, our findings suggest that while Bifidobacterium breve and fatty acid supplementation may influence host fatty acid metabolism, further focused studies are necessary to clarify the role of eicosapentaenoic acid in managing irritable bowel syndrome.
Throughout our research, we observed significant changes in fatty acid profiles, especially in liver and serum tissues, after administering Bifidobacterium breve. Notably, in the maternally separated rats, the treatment appeared to enhance levels of palmitoleic acid, arachidonic acid, and docosahexaenoic acid in various tissues, which are fatty acids that others believe could be influential in managing symptoms related to IBS.
However, while eicosapentaenoic acid was present in the research context, it was largely studied in combination with other treatments. This made it challenging to evaluate its isolated effect on IBS directly. Thus, while we noted some positive metabolic changes with our treatment approach, the specific impact of eicosapentaenoic acid on IBS symptoms wasn’t definitively established.
Overall, our findings suggest that while Bifidobacterium breve and fatty acid supplementation may influence host fatty acid metabolism, further focused studies are necessary to clarify the role of eicosapentaenoic acid in managing irritable bowel syndrome.
Read More
Most Useful Reviews
9.5
Effective treatment
The shipping speed is swift, and after consuming the product, my bowel movements improved significantly; it effectively reduces triglycerides, which is beneficial for managing my irritable bowel syndrome.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 2 Researches
5
5
DHA effects on IBS unclear
Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel syndrome.
Combination treatment explored, limited findings
We aimed to understand the role of docosahexaenoic acid (DHA) in the context of irritable bowel syndrome (IBS) by investigating how it works alongside Bifidobacterium breve and essential fatty acids, namely α-linolenic acid and linoleic acid.
Our study involved maternally separated and non-separated rats, who received different dietary supplements for a period of seven weeks. We specifically looked for changes in colonic sensitivity and fatty acid profiles in various tissues, comparing supplemented and control groups.
The results showed that feeding B. breve to maternally separated rats notably increased levels of palmitoleic acid, arachidonic acid, and DHA in their liver, along with adjustments in other fatty acids within brain and body fat tissues. However, the same supplementation in non-separated rats elevated other fatty acids, with a significant boost in eicosapentaenoic acid and docosapentaenoic acid in their serum.
Overall, while we observed that DHA levels adjusted in response to the supplementations, the specific effects of DHA on IBS symptoms remain unclear, especially since it was administered in combination with other treatments. This indicates that more focused research on DHA alone is necessary to fully gauge its impact on IBS.
Our study involved maternally separated and non-separated rats, who received different dietary supplements for a period of seven weeks. We specifically looked for changes in colonic sensitivity and fatty acid profiles in various tissues, comparing supplemented and control groups.
The results showed that feeding B. breve to maternally separated rats notably increased levels of palmitoleic acid, arachidonic acid, and DHA in their liver, along with adjustments in other fatty acids within brain and body fat tissues. However, the same supplementation in non-separated rats elevated other fatty acids, with a significant boost in eicosapentaenoic acid and docosapentaenoic acid in their serum.
Overall, while we observed that DHA levels adjusted in response to the supplementations, the specific effects of DHA on IBS symptoms remain unclear, especially since it was administered in combination with other treatments. This indicates that more focused research on DHA alone is necessary to fully gauge its impact on IBS.
Read More
5
Fatty acids affect IBS metabolism
Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel syndrome.
Limited direct evidence of eicosapentaenoic acid
Our study focused on understanding how eicosapentaenoic acid, alongside other fatty acids, influences irritable bowel syndrome (IBS). We designed an experiment where we treated both maternally separated and non-separated rats with Bifidobacterium breve and explored its effect on colonic sensitivity and fatty acid metabolism over a period of seven weeks.
Throughout our research, we observed significant changes in fatty acid profiles, especially in liver and serum tissues, after administering Bifidobacterium breve. Notably, in the maternally separated rats, the treatment appeared to enhance levels of palmitoleic acid, arachidonic acid, and docosahexaenoic acid in various tissues, which are fatty acids that others believe could be influential in managing symptoms related to IBS.
However, while eicosapentaenoic acid was present in the research context, it was largely studied in combination with other treatments. This made it challenging to evaluate its isolated effect on IBS directly. Thus, while we noted some positive metabolic changes with our treatment approach, the specific impact of eicosapentaenoic acid on IBS symptoms wasn’t definitively established.
Overall, our findings suggest that while Bifidobacterium breve and fatty acid supplementation may influence host fatty acid metabolism, further focused studies are necessary to clarify the role of eicosapentaenoic acid in managing irritable bowel syndrome.
Throughout our research, we observed significant changes in fatty acid profiles, especially in liver and serum tissues, after administering Bifidobacterium breve. Notably, in the maternally separated rats, the treatment appeared to enhance levels of palmitoleic acid, arachidonic acid, and docosahexaenoic acid in various tissues, which are fatty acids that others believe could be influential in managing symptoms related to IBS.
However, while eicosapentaenoic acid was present in the research context, it was largely studied in combination with other treatments. This made it challenging to evaluate its isolated effect on IBS directly. Thus, while we noted some positive metabolic changes with our treatment approach, the specific impact of eicosapentaenoic acid on IBS symptoms wasn’t definitively established.
Overall, our findings suggest that while Bifidobacterium breve and fatty acid supplementation may influence host fatty acid metabolism, further focused studies are necessary to clarify the role of eicosapentaenoic acid in managing irritable bowel syndrome.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.6
9.5
Effective treatment
The shipping speed is swift, and after consuming the product, my bowel movements improved significantly; it effectively reduces triglycerides, which is beneficial for managing my irritable bowel syndrome.
